{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:09:18Z","timestamp":1775876958150,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.drugalcdep.2024.111112","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T19:27:00Z","timestamp":1706815620000},"page":"111112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis"],"prefix":"10.1016","volume":"256","author":[{"given":"Gary","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L.","family":"Brandeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2024.111112_bib1","unstructured":"Agency for Health Care Research and Quality, 2023. Using appropriate price indices for analyses of health care expenditures or income across multiple years. https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml#t2a1."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103877","article-title":"Methadone and buprenorphine-related deaths among people prescribed and not prescribed opioid agonist therapy during the COVID-19 pandemic in England","volume":"110","author":"Aldabergenov","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: opioid use disorder and COVID-19","volume":"173","author":"Alexander","year":"2020","journal-title":"Ann. Intern Med."},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111112_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111112_bib5","first-page":"1","article-title":"United States life tables, 2017","volume":"68","author":"Arias","year":"2019","journal-title":"Natl. Vital.-. Stat. Rep."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111112_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/papr.12097","article-title":"Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration","volume":"14","author":"Baser","year":"2014","journal-title":"Pain. Pract."},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.111112_bib7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1360-0443.2010.03014.x","article-title":"The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective","volume":"105","author":"Bell","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19","volume":"131","author":"Brothers","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"7052","key":"10.1016\/j.drugalcdep.2024.111112_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.313.7052.264","article-title":"Characteristics of fatal methadone overdose in Manchester, 1985-94","volume":"313","author":"Cairns","year":"1996","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.111112_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32795","article-title":"Analysis of substance use disorder treatment admissions in the US by sex and race and ethnicity before and during the COVID-19 pandemic","volume":"5","author":"Cantor","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2015.12.026","article-title":"Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study","volume":"160","author":"Carlson","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study","volume":"46","author":"Carroll","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib13","unstructured":"CDC, 2022. Drug Overdose Deaths in the United States, 2001\u20132021. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db457.htm. (Accessed May 5 2023)."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib14","unstructured":"Center for the Evaluation of Value and Risk in Health, 2023. CEA Registry. https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib16","first-page":"61068","volume":"81","author":"Department of Defense","year":"2016"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108197","article-title":"Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic","volume":"121","author":"Dunn","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111112_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108276","article-title":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","volume":"123","author":"Figgatt","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib21","unstructured":"Frank, R.G., Humphreys, K., Huskamp, H.A., 2023. Comments on medications for the treatment of opioid use disorder. https:\/\/www.brookings.edu\/opinions\/comments-on-medications-for-the-treatment-of-opioid-use-disorder\/. (Accessed June 5 2023)."},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111112_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.36298","article-title":"Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic","volume":"5","author":"Frost","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111112_bib23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/add.15847","article-title":"What lessons from Sweden's experience could be applied in the United States in response to the addiction and overdose crisis?","volume":"117","author":"Fugelstad","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108896","article-title":"Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic","volume":"143","author":"Hallgren","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111112_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36914","article-title":"Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for Medicaid enrollees","volume":"6","author":"Hammerslag","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111112_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1235","article-title":"Racial, ethnic, and sex differences in methadone-involved overdose deaths before and after the US Federal policy change expanding take-home methadone doses","volume":"4","author":"Harris","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.drugalcdep.2024.111112_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.15288\/jsad.2019.80.693","article-title":"Increasing access to opioid use disorder treatment: assessing state policies and the evidence behind them","volume":"80","author":"Hinde","year":"2019","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108801","article-title":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis","volume":"141","author":"Hoffman","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108163","article-title":"The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19","volume":"120","author":"Hughto","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"10324","key":"10.1016\/j.drugalcdep.2024.111112_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","article-title":"Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission","volume":"399","author":"Humphreys","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.drugalcdep.2024.111112_bib32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111112_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108219","article-title":"Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19","volume":"122","author":"Joseph","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111579","article-title":"Examination of methadone involved overdoses during the COVID-19 pandemic","volume":"344","author":"Kaufman","year":"2023","journal-title":"Forensic Sci. Int"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib36","article-title":"COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania","volume":"155","author":"Kawasaki","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111112_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00952990.2018.1545131","article-title":"A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine","volume":"45","author":"Kelty","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109703","article-title":"Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic","volume":"242","author":"Kleinman","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann. Intern Med"},{"issue":"10118","key":"10.1016\/j.drugalcdep.2024.111112_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.drugalcdep.2024.111112_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115714119","article-title":"Modeling the evolution of the US opioid crisis for national policy development","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111112_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann. Intern Med"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111112_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1192\/pb.28.2.47","article-title":"Treatment preferences of opiate-dependent patients","volume":"28","author":"Luty","year":"2018","journal-title":"Psychiatr. Bull."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib44","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2024.111112_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111112_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1377\/hlthaff.23.4.176","article-title":"Trends in medical spending by age, 1963-2000","volume":"23","author":"Meara","year":"2004","journal-title":"Health Aff. (Millwood)"},{"issue":"Pt 2","key":"10.1016\/j.drugalcdep.2024.111112_bib47","article-title":"The intertwined expansion of telehealth and buprenorphine access from a prescriber hub","volume":"152","author":"Moore","year":"2021","journal-title":"Prev. Med"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib48","unstructured":"National Safety Council, 2023. Drug overdoses. https:\/\/injuryfacts.nsc.org\/home-and-community\/safety-topics\/drugoverdoses\/data-details\/. (Accessed May 5 2023)."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"Neumann","year":"2013","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib50","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111112_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/ADM.0000000000000774","article-title":"Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic","volume":"15","author":"Nordeck","year":"2021","journal-title":"J. Addict. Med"},{"issue":"2","key":"10.1016\/j.drugalcdep.2024.111112_bib52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","article-title":"Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.","volume":"133","author":"Otiashvili","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111112_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1018","article-title":"Overall and telehealth addiction treatment utilization by age, race, ethnicity, and socioeconomic status in California after COVID-19 policy changes","volume":"4","author":"Palzes","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111112_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109762","article-title":"Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder","volume":"243","author":"Qian","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111112_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09595230500263939","article-title":"The relationship between take-away methadone policies and methadone diversion","volume":"24","author":"Ritter","year":"2005","journal-title":"Drug Alcohol Rev."},{"issue":"12","key":"10.1016\/j.drugalcdep.2024.111112_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050673","article-title":"Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia","volume":"7","author":"Ruger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib58","article-title":"Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study","volume":"129","author":"Russell","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib59","unstructured":"SAMSHA, 2019. National Survey on Drug Use and Health 2018 (NSDUH-2018-DS0001). https:\/\/www.datafiles.samhsa.gov\/study-dataset\/national-survey-drug-use-and-health-2018-nsduh-2018-ds0001-nid18758. (Accessed June 14 2020)."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib60","unstructured":"SAMSHA, 2020a. Leveraging Existing Health and Disease Management Programs to Provide Mental Health and Substance Use Disorder Resources During the COVID-19 Public Health Emergency (PHE). https:\/\/www.samhsa.gov\/coronavirus. (Accessed May 6 2023)."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib61","unstructured":"SAMSHA, 2020b. Methadone Take-Home Flexibilities Extension Guidance. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance. (Accessed May 6 2023)."},{"key":"10.1016\/j.drugalcdep.2024.111112_bib62","series-title":"Medications for the Treatment of Opioid Use Disorder: Notice of Proposed Rule Making","first-page":"77330","author":"SAMSHA","year":"2022"},{"issue":"10","key":"10.1016\/j.drugalcdep.2024.111112_bib63","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.drugalcdep.2024.111112_bib64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1185\/03007995.2015.1016607","article-title":"Sources of prescription opioids among diagnosed opioid abusers","volume":"31","author":"Shei","year":"2015","journal-title":"Curr. Med Res Opin."},{"issue":"1","key":"10.1016\/j.drugalcdep.2024.111112_bib65","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/08897077.2022.2060438","article-title":"The idea is to help people achieve greater success and liberty: a qualitative study of expanded methadone take-home access in opioid use disorder treatment","volume":"43","author":"Suen","year":"2022","journal-title":"Subst. Abus"},{"issue":"12","key":"10.1016\/j.drugalcdep.2024.111112_bib66","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.drugalcdep.2024.111112_bib67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000446429","article-title":"Methadone-related overdose deaths in a liberal opioid maintenance treatment programme","volume":"22","author":"Tjagvad","year":"2016","journal-title":"Eur. Addict. Res"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib68","unstructured":"U.S. Census Bureau, 2020. American Community Survey 2018, 5-year estimates -- public use microdata sample. https:\/\/data.census.gov\/mdat\/#\/search?ds=ACSPUMS5Y2018&cv=SEX&rv=AGEP&wt=PWGTP. (Accessed May 6 2023)."},{"issue":"7","key":"10.1016\/j.drugalcdep.2024.111112_bib69","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s11606-021-06969-1","article-title":"Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US veterans","volume":"37","author":"Vakkalanka","year":"2022","journal-title":"J. Gen. Intern Med"},{"key":"10.1016\/j.drugalcdep.2024.111112_bib70","article-title":"Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study","volume":"28","author":"Williams","year":"2023","journal-title":"Lancet Reg. Health Am."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871624000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:31:52Z","timestamp":1759829512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871624000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":70,"alternative-id":["S0376871624000334"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111112","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111112"}}